Clinical trials in Amadora – page 2

31 clinical trials in Amadora, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PortugalEnsaios-Clinicos.pt

Amadora at a glance

clinical trials

Research sites1

Quick filters

31 trials in Amadora

Open in trial search

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Momelotinib Dihydrochloride Monohydrate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

HIV infection

Not yet recruiting

Safety and efficacy of GS-3242 drug combination compared with standard drug combination in treatment‑naive adults with HIV‑1

Registered drugNo placebo

Safety and efficacy of GS-3242 drug combination compared with standard drug combination in treatment‑naive adults with HIV‑1

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Bictegravir
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Urinary tract infection

Not yet recruiting

MV140 for Women with Recurrent Uncomplicated Urinary Tract Infections

Registered drug

MV140 for Women with Recurrent Uncomplicated Urinary Tract Infections

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Ascorbic Acid
Sponsor:Inmunotek S.L.

Contact Research Centre

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational

Portugal

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Asundexian
Sponsor:Bayer AG

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting

Registered drugNo placebo

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:AstraZeneca AB

Contact Research Centre

HIV infection

Not recruiting

Study of Weekly Oral GS-1720 and GS-4182 for Untreated HIV-1 Patients

Registered drugNo placebo

Study of Weekly Oral GS-1720 and GS-4182 for Untreated HIV-1 Patients

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Bictegravir
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Abemaciclib, Letrozole, and Fulvestrant for Patients with Advanced HR-positive/HER2-negative Breast Cancer

Registered drugNo placebo

Study on Abemaciclib, Letrozole, and Fulvestrant for Patients with Advanced HR-positive/HER2-negative Breast Cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Fulvestrant
Sponsor:Medica Scientia Innovation Research S.L.

Contact Research Centre

Non-small cell lung cancer+1

Not recruiting

Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Asthma

Not recruiting

Study on the Effectiveness and Safety of Budesonide, Glycopyrronium, and Formoterol Inhaler for Adults and Adolescents with Severe Asthma

Registered drug

Study on the Effectiveness and Safety of Budesonide, Glycopyrronium, and Formoterol Inhaler for Adults and Adolescents with Severe Asthma

Registered drug

Portugal

Participants:0–17 years · 18–64 years · 65+ years
Substances:Budesonide
Sponsor:AstraZeneca AB

Contact Research Centre

Malignant peritoneal neoplasm+2

Not recruiting

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Amadora

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for HER2-positive and triple-negative variants. Research evaluates new therapeutic approaches for ovarian cancer and non-small cell lung cancer.

Chemotherapy-free treatments for HER2+ breast cancer
Advanced therapies for platinum-resistant ovarian cancer
Combination immunotherapy approaches

Multiple studies exploring targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Clinical research targeting systemic lupus erythematosus and related conditions. Studies evaluate novel treatments for scleroderma-related lung disease and inflammatory conditions.

Long-term safety studies for lupus treatments
Interstitial lung disease interventions
Novel therapeutic approaches for autoimmune disorders

Focus on developing safer and more effective treatments for chronic autoimmune conditions.

03 Cardiovascular and Metabolic Disorders

Research examining treatments for Type 2 diabetes with cardiovascular complications. Studies investigating new approaches for stroke prevention and vascular health.

Diabetes cardiovascular outcomes
Post-stroke treatment strategies
Vascular disease management

Comprehensive evaluation of therapeutic interventions for complex cardiometabolic conditions.

Back to Portugal All countries